Nifoksipam

Nifoxipam is a synthetic depressant of the nitrobenzodiazepine class and an active metabolite of flunitrazepam. It has potential applications in the short-term management of anxiety, insomnia, and acute seizures, but is currently available exclusively through research chemical vendors as a novel psychoactive substance. As with other benzodiazepines, it carries a risk of dependence and habit formation with repeated use.

Also known as: Dp 370, 3-oh-norflunitrazepam

Classification

Chemical: Benzodiazepine
Psychoactive: Depressant
Tag: Anxiolytic
Tag: GABAergic
Tag: Habit-Forming
Tag: Hypnotic
Tag: Research-Chemical
Tag: Sedative
Tag: Tentative

Effects

Sedation
Muscle Relaxation
Respiratory Depression
Anxiolytic
Sedative
Dystaxia
Anxiety Suppression
Thought Deceleration
Information Processing Suppression
Euphoria
Amnesia
Compulsive Redosing
Disinhibition
Dulled Perception

Routes of Administration

Oral

Dosage

Heavy: 2 mg
Light: 0.1 – 0.5 mg
Common: 0.5 – 1 mg
Strong: 1 – 2 mg
Threshold: 0.1 mg

Duration

Onset: 0.17-1.25 h
After Effects: 1-24 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu